PDGFRB and melanoma: Moreover, in light of our recent description of P-Rex1 as a key driver of melanoma progression in vivo[14], it is noteworthy that a common mechanism of acquired resistance to novel therapeutic kinase inhibitors in BRAFV600E driven melanoma is upregulation of PDGFRβ [30], [31].